Article Text

2012 NIH BrIDGs Projects Announced

Statistics from

The National Institutes of Health (NIH) announced projects selected to receive 2012 Bridging Interventional Development Gaps (BrIDGs) support. BrIDGs, formerly known as NIH Rapid Access to Interventional Development, is supported by the NIH Common Fund. Rather than funding successful applicants directly, BrIDGs enables NIH contractors to provide pre-clinical services and facilitates the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

As announced by the NIH, BrIDGs selected the following new projects from its 2012 application solicitation:

  • Peritoneal Cancers

    • Tumor Penetrating Microparticles for Peritoneal Cancers

    • Jessie Au, PharMD, PhD, chief scientific officer and acting chief executive officer

    • Optimum Therapeutics, LLC, San Diego

This project focuses on cancers that affect organs in the peritoneal cavity such as the bladder, liver and pancreas. A drug delivery system, called tumor-penetrating microparticles, is under development to target peritoneal tumors.

  • Lecithin-cholesterol acyltransferase (LCAT) deficiency syndrome

    • Development of Assays to Detect Anti-drug Antibodies against ACP-501 (recombinant human LCAT)

    • Brian Krause, PhD, chief scientific officer

    • Alphacore Pharma, LLC, Ann Arbor, Mich.

Lecithin-cholesterol acyltransferase deficiency syndrome is a rare disorder that causes a drastic reduction of high-density lipoprotein (HDL) cholesterol levels in patients. This leads to disorders of the cornea (the transparent lens on the eye), anemia, and may cause kidney failure. The objective of this project is to develop a treatment called recombinant human LCAT that would act as a replacement therapy to offset the deficiency caused by LCAT deficiency syndrome.

  • Spinal Cord Injury

    • Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury

    • George Maynard, PhD, vice president, Preclinical Development

    • Axerion Therapeutics, Inc., New Haven, Conn.

Recovery after a spinal cord injury is limited, as nerve cell growth is virtually nonexistent in the adult spinal cord. This project aims to develop a compound called Nogo Receptor Decoy to …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.